Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Revenue (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Revenue for 3 consecutive years, with $1.3 million as the latest value for Q2 2025.

  • Quarterly Revenue rose 1200.0% to $1.3 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$1.4 million through Dec 2025, up 82.48% year-over-year, with the annual reading at $1.3 million for FY2025, 550.0% up from the prior year.
  • Revenue for Q2 2025 was $1.3 million at Inhibrx Biosciences, up from -$2.7 million in the prior quarter.
  • The five-year high for Revenue was $1.6 million in Q4 2023, with the low at -$8.1 million in Q1 2024.
  • Average Revenue over 3 years is -$942000.0, with a median of $100000.0 recorded in 2024.
  • The sharpest move saw Revenue crashed 93.88% in 2024, then soared 1200.0% in 2025.
  • Over 3 years, Revenue stood at $1.6 million in 2023, then plummeted by 93.88% to $100000.0 in 2024, then skyrocketed by 1200.0% to $1.3 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $1.3 million, -$2.7 million, and $100000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.